首页> 外文期刊>Medical science monitor: international medical journal of experimental and clinical research >Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma
【24h】

Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma

机译:单胺氧化酶A与肾细胞癌组织病理学亚型及肿瘤分级的表达模式比较

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Studies of the biochemical properties of MAO-A (monoamine oxidase) are numerous, but the information about determination of MAO-A in human normal and tumour renal tissue is limited. Our objectives in the present study were to determine the localization of MAO-A in normal kidney and level of expression of this protein in tumour kidney. Material/Methods: Enzyme immunohistochemical method was chosen for detection of MAO-A in 63 clinical samples of all histopathological types of RCC (renal cell carcinoma). Our results were compared to basic clinical and histopathological parameters such as histopathological type and tumour grade. We also compared MAO-A expression between normal and tumour tissue samples. Results: We confirmed the elevated expression of MAO-A in high-grade tumours of renal cell carcinoma specimens. The percentage of MAO-positive samples progressively increased from 9 in grade 2 to 45 in grade 3. We also noted high levels of MAO-A immunoreactivity in epithelial cells of proximal tubules in normal renal tissue. MAO-A was absent or very low in epithelial cells of distal tubules and glomerular capsule, as well as in endothelial cells of renal vessels. Conclusions: Taken together, our results and findings of other studies show that MAO-A expression in high-grade tumours may have a direct role in maintaining a dedifferentiated phenotype and promoting aggressive behaviour. The ability of clorgyline (an MAO-A inhibitor) to counteract oncogenic pathways and promote differentiation suggests that MAO-A inhibitors, which have been used for many years in clinical practise for treating neurological disorders, could be therapeutic options for advanced stages of tumours.
机译:背景:关于毛-A(单胺氧化酶)生化性质的研究很多,但关于在人类正常和肿瘤肾组织中测定毛-A的信息有限。本研究的目的是确定 毛-A 在正常肾脏中的定位以及该蛋白在肿瘤肾脏中的表达水平。材料/方法:选择酶免疫组化法检测所有组织病理学类型的RCC(肾细胞癌)的63个临床样本中的毛-A。我们的结果与基本的临床和组织病理学参数(如组织病理学类型和肿瘤分级)进行了比较。我们还比较了正常和肿瘤组织样本之间的毛-A表达。结果:我们证实了毛-A在肾细胞癌标本高级别肿瘤中的表达升高。毛阳性样本的百分比从2年级的9%逐渐增加到3年级的45%。我们还注意到正常肾组织近端肾小管上皮细胞的毛-A免疫反应性水平很高。毛-A在远端肾小管和肾小球囊的上皮细胞以及肾血管的内皮细胞中不存在或非常低。结论:综上所述,我们的结果和其他研究的结果表明,毛-A在高级别肿瘤中的表达可能在维持去分化表型和促进攻击性行为方面具有直接作用。Clorgyline(一种毛-A抑制剂)抵消致癌途径和促进分化的能力表明,毛-A抑制剂在临床实践中已用于治疗神经系统疾病多年,可能是晚期肿瘤的治疗选择。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号